Aim immunotech bolsters board of directors with appointment of pharmaceutical industry veteran nancy k. bryan, with deep commercial, marketing, business development and corporate finance expertise

Ocala, fla., march 30, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including covid-19, the disease caused by the sars-cov-2 virus — today announced nancy k. bryan as the newest member of its board of directors. she has also been named to a number of committees.
AIM Ratings Summary
AIM Quant Ranking